Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in an Extension Phase, if regionally applicable, until it becomes commercially available or until the study is terminated by the Sponsor.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03005327
Study type Interventional
Source X4 Pharmaceuticals
Status Active, not recruiting
Phase Phase 2
Start date December 2016
Completion date December 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03995108 - Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome Phase 3
Withdrawn NCT03087370 - A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome